For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Treatment Study for Patients with Stage IV Non-Small Cell Lung Cancer
This study looks at patients with advanced lung cancer. Participants in this study will be randomized into two groups. The first group will have radiation plus a drug (pembrolizumab). The second group will have only the drug (pembrolizumab). Tumors of participants will be measured to see if the addition of radiation changes the growth of the tumor compared to the drug alone.
In order to participate you must meet the following criteria:
- Have measurable disease based on RECIST 1.1.
- Are willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion.
- Demonstrate adequate organ function.
This is a partial list of elgibility requirements.